Immune Therapeutics, Inc. (IMUN) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
	10-K	10-K	10-K	10-K/A	10-K	10-K	10-K	10-K/A
Net income	3.6	1.6	-3.4	-8.6	-7.3	-19.5	-14.2	-48.3
Depreciation and amortization [+]		0.0	0.0	0.0	0.0	0.0	0.6	2.9
Depreciation		0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortization of intangible assets							0.6
Asset impairment charges							5.2	9.9
Stock-based compensation								2.1
Change in working capital [+]	0.7	1.0	2.7	2.1	38.5	-3.6	-4.6	2.7
Accounts receivable						0.0	0.0
Inventories			0.1	0.1	-0.2
Other current assets							0.0	0.2
Accounts payable	0.1	0.1	0.9	0.3	0.9	0.5	0.9	1.8
Accrued expenses	0.0	0.1	0.0	1.7	1.4	2.8	0.2	0.6
Other	0.6	0.8	1.7		36.3	-7.0	-5.8
Other operating activities	-4.5	-2.8	0.7	5.1	-33.2	20.3	10.2	26.8
Cash from operations	-0.2	-0.2	0.0	-1.4	-2.1	-2.8	-2.8	-3.8

Capital expenditures	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchases of property and equipment					0.0	0.0		0.0
Other cash from investing				0.0				-0.1
Cash from investing	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1

Issuance of common stock, net				0.2	0.7
Other cash from financing	0.7	0.2		1.1	1.3	2.9	2.7	3.7
Cash from financing	0.7	0.2	0.0	1.4	2.0	2.9	2.7	3.7

Free cash flow	-0.2	-0.2	0.0	-1.4	-2.1	-2.8	-2.8	-3.8
Per share (diluted)	($0.02)	($0.01)	$0.00	($3.19)	($0.01)	($0.01)	($0.02)	($0.04)

Cash paid for interest			0.0		0.0	0.0	0.0	0.0